Safety pharmacology

Toxicological Testing Handbook: Principles, Applications and Data Interpretation

Volumn , Issue , 2016, Pages 33-76

  Redfern, William S ^a   Wakefield, Ian D ^b  

^a ASTRAZENECA   (United Kingdom)

^b UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85123328447     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (268)

1. Anon. ICHS7A-Note for Guidance on Safety Pharmacology Studies for Human Pharmaceuticals. European Agency for the Evaluation of Medicinal Products, Committee for Proprietary Medicinal Products (CPMP), London, UK, 2000. Reference CPMP/ICH/539/00.
2. Sterner W, Korn WD. Zur Pharmakologie und Toxikologie von Etofyllinclofibrate. Arzneimittelforschung 1980; 30:2023-2031.
3. Anon. Japanese Guidelines for Nonclinical Studies of Drugs Manual, Pharmaceutical Affairs Bureau, Japanese Ministry of Health and Welfare, Yakugi Nippo 1995.
4. Redfern WS, Wakefield ID, Prior H, Pollard CE, Hammond TG, Valentin J-P. Safety pharmacology-a progressive approach. Fundam Clin Pharmacol 2002; 16:161-173.
5. Williams PD. The role of pharmacological profiling in safety assessment. Regul Toxicol Pharmacol 1990; 12:238-252.
6. Sullivan AT. Good laboratory practice and other regulatory issues: a European view. Drug Dev Res 1995; 35:145-149.
7. Kinter LB. General pharmacology/safety pharmacology: customers, biologics and GLPs. Drug Dev Res 1995; 35:142-144.
8. Sullivan AT, Kinter LB. Status of safety pharmacology in the pharmaceutical industry-1995. Drug Dev Res 1995; 35:166-172.
9. Kinter LB, Dixon LW. Safety pharmacology program for pharmaceuticals. Drug Dev Res 1995; 35:179-182.
10. Porsolt RD. Safety pharmacology-a critical perspective. Drug Dev Res 1997; 41:51-57.
11. Anon. Committee for Proprietary Medicinal Products (CPMP) Points to Consider: The assessment of QT interval prolongation by non-cardiovascular medicinal products, 1997. CPMP/986/96.
12. Laurence DR, Bennett PN. Clinical Pharmacology. Edinburgh: Churchill Livingstone, 1992; 121-122.
13. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA 1998; 279:1200-1205.
14. Editorial. SuperMAB on trial. Lancet 2006; 367:960.
15. Kennedy T. Maintaining the drug discovery/development interface. Drug Dis Today 1997; 2:436-444.
16. Pirmohamed M, James S, Meakin S, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 ptients. BMJ 2004; 329:15-19.
17. Shah RR. Drug-induced prolongation of the QT interval: why the regulatory concern? Fund Clin Pharmacol 2002; 16:119-124.
18. Fung M, Thornton A, Mybeck K, Hsaio-Hui Wu J, Hornbuckle K, Muniz E. Evaluation of the characteristics of safety withdrawal of prescription drugs from worldwide pharmaceutical markets-1960 to 1999. Drug Inf J 2001; 35:293-317.
19. Goldstein A, Aronow L, Kalman SM. 2nd ed. Principles of Drug Action. New York: Wiley, 1974:569-621.
20. Maurissen JPJ. Neurobehavioural methods for the evaluation of sensory functions. In: Chang LW, Slikker W, eds. Neurotoxicology-Approaches and Methods. San Diego: Academic Press, 1995:239-264.
21. Burgen ASV, Mitchell JF. 7th ed. Gaddum's Pharmacology. Oxford: Oxford University Press, 1972:226.
22. Olson H, Betton G, Robinson D, et al. Concordance of the toxicity of pharmaceuticals in humans and animals. Regul Toxicol Pharmacol 2000; 32:56-67.
23. Igarashi T, Nakane S, Kitagawa T. Predictability of clinical adverse reactions of drugs by general pharmacology studies. J Toxicol Sci 1995; 20:77-92.
24. Webster R, Leishman D, Walker D. Towards a drug concentration effect relationship for QT prolongation and torsades de pointes. Curr Opin Drug Discov Devel 2002; 5:116-126.
25. Redfern WS, Carlsson L, Davis AS, et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003; 58:32-45.
26. De Bruin ML, Pettersson M, Meyboom RHB, Hoes AW, Leufkens HGM. Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death. Eur Heart J 2005; 26:590-597.
27. Fuenmayor LD, Diaz S. The effect of fasting on the stereotyped behaviour induced by amphetamine and by apomorphine in the albino rat. Eur J Pharmacol 1984; 99:153-158.
28. Hammond TG, Carlsson L, Davis AS, et al. Methods of collecting and evaluating non-clinical cardiac electrophysiology data in the pharmaceutical industry: results of an international survey. Cardiovasc Res 2000; 49:741-750.
29. Valentin JP, Bass AS, Atrakchi A, Olejniczak K, Kannosuke F. Challenges and lessons learned since implementation of the safety pharmacology guidance ICH S7A. J Pharmacol Toxicol Methods 2005; 52:22-29.
30. Bass A, Lewis Kinter L, Williams P. Origins, practices and future of safety pharmacology. J Pharmacol Toxicol Methods 2004; 49:145-151.
31. Lees KR. Cerestat and other NMDA antagonists in ischemic stroke. Neurology 1997; 4:S66-S69.
32. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Cardiovasc Res 2000; 47:219-233 (published simultaneously in Eur Heart J 2000;21:1216-1231).
33. Cavero I, Mestre M, Guillon J-M, Crumb W. Drugs that prolong QT interval as an unwanted effect: assessing their likelihood of inducing hazardous cardiac dysrhythmias. Expert Opin Pharmacother 2000; 1:947-973.
34. Gralinski MR. The assessment of potential for QT interval prolongation with new pharmaceuticals: impacton drugdevelopment. JPharmacol ToxicolMethods 2000; 43:91-99.
35. Fermini B, Fossa AA. The impact of drug-induced QT interval prolongation on drug discovery and development. Nature Reviews. Drug Discov 2003; 2:439-447.
36. Shah RR. Drug-induced QT interval prolongation: regulatory perspectives and drug development. Ann Med 2004; 36:47-52.
37. Fenichel RR, Malik M, Antzelevitch C, et al. Independent academic task force. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 2004; 15:475-495.
38. Guth BD, Germeyer S, Kolb W, Markert M. Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization. J Pharmacol Toxicol Methods 2004; 49:159-169.
39. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC. A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 2000; 97:12329-12333.
40. Vandenberg JI, Walker BD, Campbell TJ. HERG K+ channels: friend and foe. Trends Pharmacol Sci 2001; 22:240-246.
41. Bennett PB, Guthrie HR. Trends in ion channel drug discovery: advances in screening technologies. Trends Biotechnol 2003; 21:563-569.
42. Netzer R, Bischoff U, Ebneth A. HTS techniques to investigate the potential effects of compounds on cardiac ion channels at early-stages of drug discovery. Curr Opin Drug Discov Devel 2003; 6:462-469.
43. Brown AM. Drugs, hERG and sudden death. Cell Calcium 2004; 35:543-547.
44. Guthrie H, Livingston FS, Gubler U, Garippa R. A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the IonWorks HTTMsystem. J Biomol Screening, 2005; 10:832-840.
45. Aronov AM. Predictive in silico modelling for hERG channel blockers. Drug Discov Today Biosilico 2005; 10:149-155.
46. Brockway BP, Mills PA, Azar SH. A new method for continuous chronic measurement and recording of blood pressure, heart rate and activity in the rat via radio-telemetry. Clin Exp Hypertens 1991; 13:885-895.
47. Gras J, Llenas J, Palacios JM, Roberts DJ. The role of ketoconazole in the QTc interval prolonging effects of H1-antihistamines in a guinea-pig model of arrhythmogenicity. Br J Pharmacol 1996; 119:187-188.
48. Carlsson L, Amos GJ, Andersson B, Drews L, Duker G, Wadstedt G. Electrophysiological characterization of the prokinetic agents cisapride and mosapride in vivo and in vitro: implications for proarrhythmic potential? J Pharmacol Exp Ther 1997; 282:220-227.
49. Bollen P, Ellegaard L. The Gottingen minipig in pharmacology and toxicology. Pharmacol Toxicol 1997; 2:3-4.
50. Meng H, McVey M, Perrone M, Clark KL. Intravenous AMP 579, a novel adenosine A(1)/A(2a) receptor agonist, induces a delayed protection against myocardial infarction in minipig. Eur J Pharmacol 2000; 387:101-105.
51. Oguchi Y, Hamlin RL. Rate of change of QT interval in response to a sudden change in the heart rate in dogs. Am J Vet Res 1994; 55:1618-1623.
52. Fridericia L. Dir Systolendaeur in elektrokardiogram bei normalen menchen und bei herzkranken. Acta Medica Scandinavica 1920; 53:469-486.
53. Van de Water A, Verheyen J, Xhonneux R, Reneman RS. An improved method to correct the QT interval of the electrocardiogram for changes in heart rate. J Pharmacol Methods 1989; 22:207-217.
54. Matsunaga T, Mitsui T, Harada T, et al. QT corrected for heart rate and relation between QT and RR intervals in beagle dogs. J Pharmacol Toxicol Methods 1997; 38:201-209.
55. Tattersall ML, Dymond M, Hammond T, Valentin J-P. Correction of QT values to allow for increases in heart rate in conscious Beagle dogs in toxicology assessment. J Pharmacol Toxicol Methods, 2006; 53:11-19.
56. Batey AJ, Doe CPA. A method for QT correction based on beat-to-beat analysis of the QT/RR interval relationship in conscious telemetered beagle dogs. J Pharmacol Toxicol Methods 2002; 48:11-19.
57. Fossa AA, Wisialowski T, Magnano A, et al. Dynamic beat-to-beat modeling of the QT-RR interval relationship: analysis of QT prolongation during alterations of autonomic state versus human ether a-go-go-related gene inhibition. J Pharmacol Exp Ther 2005; 312:1-11.
58. Schneider J, Hauser R, Andreas J-O, Linz K, Jahnel U. Differential effects of human ether-ago-go-related gene (HERG) blocking agents on QT duration variability in conscious dogs. Eur J Pharmacol 2005; 512:53-60.
59. van der Linde H, Van de Water A, Loots W, et al. A new method to calculate the beat-to-beat instability of QT duration in drug-induced long QT in anesthetized dogs. J Pharmacol Toxicol Methods 2005; 52:168-177.
60. Bode G, Olejniczak K. ICH Expert Working Group, ICH topic: the draft ICH S7B step 2: note for guidance on safety pharmacology studies for human pharmaceuticals. Fund Clin Pharmacol 2002; 16:105-118.
61. Anon. Note for guidance on the nonclinical evaluation of the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals (CHMP/ICH/423/02). European Medicines Agency, Committee for Human Medicinal Products (CHMP), London, U.K., 2005. www.emea.eu.int/pdfs/human/ich/042302en.pdf.
62. Cavero I, Crumb W. ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis. Expert Opin Drug Saf 2005; 4:509-530.
63. Gintant GA, Limberis JT, McDermott JS, Wegner CD, Cox BF. The canine Purkinje fibre: an in vitro model system for acquired long QT syndrome and drug-induced arrythmogenesis. J Cardiovasc Pharmacol 2001; 37:607-618.
64. Guth BD, Germeyer S, Kolb W, Markert M. Developing a strategy for the nonclinical assessment of proarrhythmic risk of pharmaceuticals due to prolonged ventricular repolarization. J Pharmacol Toxicol Methods 2004; 49:159-169.
65. Abi-Gerges N, Small BG, Lawrence CL, Hammond TG, Valentin J-P. Evidence for gender differences in electrophysiological properties of canine Purkinje fibres. Br J Pharmacol 2004; 142:1255-1264.
66. Herron W, Towers C, Templeton A. Experiences in method development for the analysis of in vitro study solutions for content. J Pharmacol Toxicol Methods 2004; 49:211-216.
67. Lawrence CL, Pollard CE, Hammond TG, Valentin J-P. Nonclinical proarrhythmia models: Predicting Torsades de Pointes. J Pharmacol Toxicol Methods 2005; 52:46-59.
68. Wilson LD, Said T, Rosenbaum DS. Disease models for elucidation of mechanisms and prediction of drug-induced proarrhythmia. Drug Discov Today Dis Models 2005; 2:205-213.
69. Hondeghem LM, Carlsson L, Duker G. Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 2001; 103:2004-2013.
70. Belardinelli L, Antzelevitch C, Vos MA. Assessing predictors of drug-induced torsade de pointes. Trends Pharmacol Sci 2003; 24:619-625.
71. Carlsson L, Almgren O, Duker G. QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions. J Cardiovasc Pharmacol 1990; 16:276-285.
72. Johansson M, Carlsson L. Female gender does not influence the magnitude of ibutilide-induced repolarization delay and incidence of torsades de pointes in an in vivo rabbit model of the acquired long QT syndrome. J Cardiovasc Pharmacol Ther 2001; 6:247-254.
73. Weissenburger J, Chezalviel F, Davy JM, et al. Methods and limitations of an experimental model of long QT syndrome. J Pharmacol Methods 1991; 26:23-42.
74. Sugiyama A, Satoh Y, Shiina H, Takeda S, Hashimoto K. Torsadegenic action of the antipsychotic drug sulpiride assessed using in vivo canine models. J Cardiovas Pharmacol 2002; 40:235-245.
75. Valentin JP, Hoffmann P, De Clerck F, Hammond TG, Hondeghem L. Review of the predictive value of the Langendorff heart model (Screenit system) in assessing the proarrhythmic potential of drugs. J Pharmacol Toxicol Methods 2004; 49:171-181.
76. Schram G, Zhang L, Derakhchan K, Ehrlich JR, Belardinelli L, Nattel S. Ranolazine: ion-channel-blocking actions and in vivo electrophysiological effects. Br J Pharmacol 2004; 142:1300-1308.
77. Fleming T, Nissen SE, Borer JS, Armstrong PW. Cardiovascular and Renal Drugs Advisory Committee: U.S. Food and Drug Administration. Report from the 100th Cardiovascular and Renal Drugs Advisory Committee meeting: U.S. Food and Drug Administration: December 8-9, 2003 Gaithersburg, MD. Circulation 2004; 109:e9004-e9005.
78. Antzelevitch C, Belardinelli L, Wu L, et al. Electrophysiologic properties and antiarrhythmic actions of a novel antianginal agent. J Cardiovasc Pharmacol Ther 2004; 9:S65-S83.
79. Antzelevitch C, Belardinelli L, Zygmunt AC, et al. Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 2004; 110:904-910.
80. Wu L, Shryock JC, Song Y, Li Y, Antzelevitch C, Belardinelli L. Antiarrhythmic Effects of Ranolazine in a Guinea Pig in Vitro Model of Long-QT Syndrome. J Pharmacol Exp Ther 2004; 310:599-605.
81. Song Y, Shryock JC, Wu L, Belardinelli L. Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes. J Cardiovasc Pharmacol 2004; 44:192-199.
82. Boyett MR, Honjo H, Kodama I. The sinoatrial node, a heterogeneous pacemaker structure. Cardiovasc Res 2000; 47:658-687.
83. Cho HS, Takano M, Noma A. The electrophysiological properties of spontaneously beating pacemaker cells isolated from mouse sinoatrial node. J Physiol 2003; 550:169-180.
84. Gillespie JS, Muir TC. A method of stimulating the complete sympathetic outflow from the spinal cord to blood vessels in the pithed rat. Br J Pharmacol 1967; 30:78-87.
85. Grant TL, McGrath JC, O'Brien JW. The influence of blood gases on alpha 1- and alpha 2-adrenoceptor-mediated pressor responses in the pithed rat. Br J Pharmacol 1985; 86:69-77.
86. Brown CM, MacKinnon AC, Redfern WS, et al. The pharmacology of RS-15385-197, a potent and selective α2-adrenoceptor antagonist. Br J Pharmacol 1993; 108:516-525.
87. Valentin JP, Bessac AM, Colpaert FC, John GW. Use of the pithed rat model to determine the relative potencies of 5-HT2A/2C receptor antagonists following acute intravenous and oral administration. Methods Find Expert Clin Pharmacol 1995; 17:267-271.
88. Zhuo J, Ohishi M, Mendelsohn FA. Roles of AT1 and AT2 receptors in the hypertensive Ren-2 gene transgenic rat kidney. Hypertension 1999; 33:347-353.
89. Van Dorpe J, Smeijers L, Dewachter I, et al. Prominent cerebral amyloid angiopathy in transgenic mice overexpressing the london mutant of human APP in neurons. Am J Pathol 2000; 157:1283-1298.
90. Tabrizchi R, Pugsley MK. Methods of blood flow measurement in the arterial circulatory system. J Pharmacol Toxicol Methods 2000; 44:375-384.
91. Koistinaho M, Kettunen MI, Goldsteins G, et al. Beta-amyloid precursor protein transgenic mice that harbor diffuse A beta deposits but do not form plaques show increased ischemic vulnerability: role of inflammation. Proc Nat Acad Sci USA 2002; 99:1610-1615.
92. Gardiner SM, Kemp PA, March JE, Woolley J, Bennett T. The influence of antibodies to TNF-alpha and IL-1beta on haemodynamic responses to the cytokines, and to lipopoly--saccharide, in conscious rats. Br J Pharmacol 1998; 125:1543-1550.
93. Wakefield ID, March JE, Kemp PA, Valentin JP, Bennett T, Gardiner SM. Comparative regional haemodynamic effects of the nitric oxide synthase inhibitors, S-methyl-L-thiocitrulline and L-NAME, in conscious rats. Br J Pharmacol 2003; 139:1235-1243.
94. Prinzen FW, Glenny RW. Developments in non-radioactive microsphere techniques for blood flow measurement. Cardiovasc Res 1994; 28:1467-1475.
95. Takahara A, Dohmoto H, Yoshimoto R, Sugiyama A, Hashimoto K. Cardiovascular action of a cardioselective Ca(2 +)channel blocker AH-1058 in conscious dogs assessed by telemetry. Eur J Pharmacol 2001; 413:101-108.
96. Little RA, Redfern WS. A method for studying baroreflex bradycardia in the unanaesthetized rat. Br J Pharmacol 1981; 74:308P-309P.
97. Kuwahara M, Yayou K, Ishii K, Hashimoto S, Tsubone H, Sugano S. Power spectral analysis of heart rate variability as a new method for assessing autonomic activity in the rat. J Electrocardiol 1994; 27:333-337.
98. Calvert CA. Heart rate variability. Vet Clin North Am Small Anim Pract 1998; 28:1409-1427 viii.
99. Irwin S. Comprehensive behavioural assessment: 1a A systematic quantitative procedure for assessing the behavioural and physiologic state of the mouse. Psychopharmacology 1968; 13:222-257.
100. Moser VC. Screening approaches to neurotoxicity: A functional observational battery. J Am Coll Toxicol 1989; 8:85-93.
101. Tilson HA, Moser VC. Comparison of screening approaches. NeuroToxicology 1992; 13:1-14.
102. Porsolt RD, McArthur RA, Lenegre A. Psychotropic screening procedures. In: van Haaren F, ed. Methods in Behavioral Pharmacology. Amsterdam: Elsevier, 1993:23-51.
103. Porsolt RD, Lemaire M, Dürkmüller N, Roux S. New perspectives in CNS safety pharmacology. Fundam Clin Pharmacol 2002; 16:197-207.
104. Trabace L, Cassano T, Steardo L, et al. Biochemical and neurobehavioral profile of CHF2819, a novel, orally active acetylcholinesterase inhibitor for Alzheimer's disease. J Pharmacol Exp Ther 2000; 294:187-194.
105. Redfern WS, Strang I, Storey S, et al. Spectrum of effects detected in the rat Functional Observational Battery following oral administration of non-CNS targeted compounds. J Pharmacol Toxicol Methods 2005; 52:77-82.
106. Haggerty GC. Development of Tier I neurobehavioral testing capabilities for incorporation into pivotal rodent safety assessment studies. J Am Coll Toxicol 1989; 8:53-69.
107. Mattson JL, Spencer PJ, Albee RR. A performance standard for clinical and Functional Observational Battery examination of rats. J Am Coll Toxicol 1996; 15:239-250.
108. Moser VC, Becking GC, MacPhail RC, Kulig BM. The IPCS collaborative study on neurobehavioral screening methods. Fundam Appl Toxicol 1997; 35:143-151.
109. Baird SJS, Catalano PJ, Ryan LM, Evans JS. Evaluation of effect profiles: Functional Observational Battery Outcomes. Fundam Appl Toxicol 1997; 40:37-51.
110. Moser VC. The functional observational battery in adult and developing rats. Neurotoxicol-ogy 2000; 21:989-996.
111. Gad SC, Gad SE. A functional observational battery for use in canine toxicity studies: development and validation. Int J Toxicol 2003; 22:415-422.
112. Patterson JP, Markgraf CG, Cirino M, Bass AS. Validation of a motor activity system by a robotically controlled vehicle and using standard reference compounds. J Pharmacol Toxicol Methods 2005; 52:159-167.
113. Vorhees CV, Acuff-Smith KD, Minck DR, Butcher RE. A method for measuring locomotor activity in rodents: contrast-sensitive computer-controlled video tracking activity assessment in rats. Neurotoxicol Teratol 1992; 14:43-49.
114. Kelley AE. Locomotor activity and exploration. In: van Haaren F, ed. Methods in Behavioral Pharmacology. Amsterdam: Elsevier, 1993:499-518.
115. Kelley AE. Locomotor activity and exploration. In: Sahgal A, ed. In: Behavioural Neuroscience: A Practical Approach, Vol. II. Oxford: IRL Press, 1993:1-21.
116. Bogo V, Hill TA, Young RW. Comparison of accelerod and rotarod sensitivity in detecting ethanol- and acrylamide-induced performance decrement in rats: review of experimental considerations of rotating rod systems. Neurotoxicology 1981; 2:765-787.
117. Hamm RJ, Pike BR, O'Dell DM, Lyeth BG, Jenkins LW. The rotarod test: an evaluation of its effectiveness in assessing motor deficits following traumatic brain injury. J Neurotrauma 1994; 11:187-196.
118. Piot-Grosjean O, Wahl F, Gobbo O, Stutzmann J-M. Assessment of sensorimotor and cognitive deficits induced by a moderate traumatic injury in the right parietal cortex of the rat. Neurobiol Dis 2001; 8:1082-1093.
119. Stanley JL, Lincoln RJ, Brown TA, McDonald LM, Dawson GR, Reynolds DS. The mouse beam walking assay offers improved sensitivity over the mouse rotarod in determining motor coordination deficits induced by benzodiazepines. J Psychopharmacol 2005; 19:221-227.
120. Clarke KA. A technique forthe study of spatiotemporal aspects of paw contact patterns, applied to rats treated with a TRH analogue. Behav Res Methods Instrum Comput 1992; 24:407-H1.
121. Hamers FPT, Lankhorst AJ, Van Laar TJ, Veldhuis WB, Gispen WH. Automated quantitative gait analysis during overground locomotion in the rat: Its application to spinal cord contusion and transaction injuries. J Neurotrauma 2001; 18:187-201.
122. Artur SP, Varejao DVM, Cabrita AM, et al. Functional assessment of peripheral nerve recovery in the rat: gait kinematics. Microsurgery 2001; 21:383-388.
123. Coulthard P, Pleuvry P, Brewster M, Wilson KL, Macfarlane TV. Gait analysis as an objective measure in a chronic pain model. J Neurosci Methods 2002; 116:197-213.
124. Handley SL, Mithani S. Effects of alpha-adrenoceptor agonists and antagonists in a maze-exploration model of "fear"-motivated behaviour. Naunyn-Schmied. Arch Pharmacol 1984; 327:1-5.
125. Pellow S, Chopin P, File SE, Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 1985; 14:149-167.
126. Handley SL, McBlane JW. An assessment of the elevated X-maze for studying anxiety and anxiety-modulating drugs. J Pharmacol Toxicol Methods 1993; 29:129-133.
127. Redfern WS, Williams A. A re-evaluation of the role of α2-adrenoceptors in the anxiogenic effects of yohimbine, using the selective antagonist delequamine in the rat. Br J Phamacol 1996; 116:2081-2089.
128. Authier N, Gillet J-P, Fialip J, Eschalier A, Coudore F. Description of a short-term Taxol®-induced nociceptive neuropathy in rats. Brain Res 2000; 887:239-249.
129. Polomano RC, Mannes AJ, Clark US, Bennett GJ. A painful peripheral neuropathy in the rat produced by the chemotherapeutic drug, paclitaxel. Pain 2001; 94:293-304.
130. Hole K, Tjølsen A. The tail-flick and formalin tests in rodents: changes in skin temperature as a confounding factor. Pain 1993; 53:247-254.
131. Sawamura S, Tomioka T, Hanaoka K. The importance of tail temperature monitoring during tail-flick test in evaluating the antinociceptive action of volatile anesthetics. Acta Anaesthesiol Scand 2002; 46:451-454.
132. Redfern WS, MacLean MR, Clague RU, McGrath JC. The role of α2-adrenoceptors in the vasculature of the rat tail. Br J Pharmacol 1995; 114:1724-1730.
133. Sotgiu ML, Castagna A, Lacerenza M, Marchettini P. Pre-injury lidocaine treatment prevents thermal hyperalgesia and cutaneous thermal abnormalities in a rat model of peripheral neuropathy. Pain 1995; 61:3-10.
134. Romanovsky AA, Ivanov AI, Shimansky YP. Selected contribution: ambient temperature for experiments in rats: a new method for determining the zone of thermal neutrality. J Appl Physiol 2002; 92:2667-2679.
135. Dyer RS. The use of sensory evoked potentials in toxicology. Fund Appl Toxicol 1984; 5:24-10.
136. Herr DW, Graff JE, Derr-Yellin EC, Crofton KM, Kodavanti PRS. Flash-, somatosensory-, and peripheral nerve-evoked potentials in rats perinatally exposed to Aroclor 1254. Neurotoxicol Teratol 2001; 23:591-601.
137. Herr DW, Boyes WK. Electrophysiological analysis of complex brain systems: sensory-evoked potentials and their generators. In: Chang LW, Slikker W, eds. Neurotoxicology: Approaches and Methods. San Diego: Academic Press, 1995:205-221.
138. Melena J, Safa R, Graham M, Casson RJ, Osborne NN. The monocarboxylate transport inhibitor, alpha-cyano-4-hydroxycinnamate, has no effect on retinal ischemia. Brain Res 2003; 989:128-134.
139. Pinilla I, Lund RD, Sauve Y. Contribution of rod and cone pathways to the dark-adapted electroretinogram (ERG) b-wave following retinal degeneration in RCS rats. Vision Res 2004; 44:2467-2474.
140. Nixon PJ, Bui BV, Armitage JA, Vingrys AJ. The contribution of cone responses to rat electroretinograms. Clin Exp Ophthalmol 2001; 29:193-196.
141. Xu L, Ball SL, Alexander KR, Peachey NS. Pharmacological analysis of the rat cone electroretinogram. Vis Neurosci 2003; 20:297-306.
142. Jones RD, Brenneke CJ, Hoss HE, Loney ML. An electroretinogram protocol for toxicological screening in the canine model. Toxicol Lett 1994; 70:223-234.
143. Lashley KS. The mechanism of vision: I. A method for rapid analysis of pattern vision in the rat. J Gen Psychol 1930; 37:453-460.
144. Prusky GT, West PW, Douglas RM. Behavioral assessment of visual acuity in mice and rats. Vis Res 2000; 40:2201-2209.
145. Prusky GT, Harker KT, Douglas RM, Whishaw IQ. Variation in visual acuity within pigmented, and between pigmented and albino rat strains. Behav Brain Res 2002; 136:339-348.
146. Prusky GT, Alam NM, Beekman S, Douglas RM. Rapid quantification of adult and developing mouse spatial vision using a virtual optomotor system. Invest Ophthalmol Vis Sci 2004; 45:4611-4616.
147. Tripathi RC, Tripathi B, Haggerty C. Drug-induced glaucomas: mechanism and management. Drug Saf 2003; 26:749-767.
148. Schnell CR, Debon C, Percicot CL. Measurement of intraocular pressure by telemetry in conscious, unrestrained rabbits. Invest Ophthalmol Vis Sci 1996; 37:958-965.
149. Reitsamer HA, Kiel JW, Harrison JM, Ransom NL, McKinnon SJ. Tonopen measurement of intraocular pressure in mice. Exp Eye Res 2004; 78:799-804.
150. Löscher W, Fassbender CP, Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs II. Maximal electroshock seizure models. Epilepsy Res 1991; 8:79-94.
151. Kitano Y, Usui C, Takasuna K, Hirohashi M, Nomura M. Increasing-current electroshock seizure test: a new method for assessment of anti- and pro-convulsant activities of drugs in mice. J Pharmacol Toxicol Methods 1996; 35:25-29.
152. De Deyn PP, D'Hooge RD, Marescau B, Pei Y-Q. Chemical models of epilepsy with some reference to their applicability in the development of anticonvulsants. Epilepsy Res 1992; 12:87-110.
153. Krall RL, Penry JK, White BG, Kupferberg HJ, Swinyard EA. Antiepileptic drug development: II. Anticonvulsant drug screening. Epilepsia 1978; 19:404-428.
154. Oliver AP, Hoffer BJ, Wyatt RJ. The hippocampal slice: a system for studying the pharmacology of seizures and for screening anticonvulsant drugs. Epilepsia 1977; 18:543-548.
155. Salazar P, Tapia R, Rogawski MA. Effects of neurosteroids on epileptiform activity induced by picrotoxin and 4-aminopyridine in the rat hippocampal slice. Epilepsy Res 2003; 55:71-82.
156. Harrison PK, Sheridan RD, Green AC, Scott IR, Tattersall JE. A guinea pig hippocampal slice model of organophosphate-induced seizure activity. J Pharmacol Exp Ther 2004; 310:678-686.
157. Freund RK, Marley RJ, Wehner JM. Differential sensitivity to bicuculline in three inbred mouse strains. Brain Res Bull 1987; 18:657-662.
158. Sebban C, Zhang XQ, Tesolin-Decros B, Millan MJ, Spedding M. Changes in EEG spectral power in the prefrontal cortex of conscious rats elicited by drugs interacting with dopaminergic and noradrenergic transmission. Br J Pharmacol 1999; 128:1045-1054.
159. Sebban C, Tesolin-Decros B, Millan MJ, Spedding M. Contrasting EEG profiles elicited by antipsychotic agents in the prefrontal cortex of the conscious rat: antagonism of the effects of clozapine by modafinil. Br J Pharmacol 1999; 128:1055-1063.
160. Dringenberg HC, Diavolitsis P, Noseworthy PA. Effect of tacrine on EEG slowing in the rat: enhancement by concurrent monoamine therapy. Neurobiol Aging 2000; 21:135-143.
161. Dimpfel W. Preclinical data base of pharmaco-specific rat EEG fingerprints (tele-stereo--EEG). Eur J Med Res 2003; 8:199-207.
162. Edgar DM, Seidel WF. Modafinil induces wakefulness without intensifying motor activity or subsequent rebound hypersomnolence in the rat. J Pharmacol Exp Ther 1997; 283:757-769.
163. Lancel M, Faulhaber J, Deisz RA. Effect of the GABA uptake inhibitor tiagabine on sleep and EEG power spectra in the rat. Br J Pharmacol 1998; 123:1471-1477.
164. Tortella FC, Hill RG. EEG seizure activity and behavioral neurotoxicity produced by (C)-MK801, but not the glycine site antagonist L-687,414, in the rat. Neuropharmacology 1996; 35:441-448.
165. Mackenzie L, Medvedev A, Hiscock JJ, Pope KJ, Willoughby JO. Picrotoxin-induced generalised convulsive seizure in rat: changes in regional distribution and frequency of the power of electroencephalogram rhythms. Clin Neurophysiology 2002; 113:586-596.
166. Maloney KJ, Cape EG, Gotman J, Jones BE. High-frequency gamma electroencephalogram activity in association with sleep-wake states and spontaneous behaviors in the rat. Neuroscience 1997; 76:541-555.
167. Takeuchi T, Harada E. Age-related changes in sleep-wake rhythm in dog. Behav Brain Res 2002; 136:193-199.
168. Pietrzak B, Czarnecka E. The effect of combined administration of ethanol and sertraline, fluoxetine and citalopram on rabbit EEG. Pharmacol Res 2003; 47:527-534.
169. Tobler I, Franken P, Jaggi K. Vigilance states, EEG spectra, and cortical temperature in the guinea pig. Am J Physiol 1993; 264:R1125-R1132.
170. Mumford H, Wetherell JR. A simple method for measuring EEG in freely moving guinea pigs. J Neurosci Methods 2001; 107:125-130.
171. McNamara RK, Skelton RW. The neuropharmacological and neurochemical basis of place learning in the Morris water maze. Brain Res Rev 1993; 18:33-49.
172. D'Hooge R, De Deyn PP. Applications of the Morris water maze in the study of learning and memory. Res Brain Res Rev 2001; 36:60-90.
173. Myhrer T. Neurotransmitter systems involved in learning and memory in the rat: a meta-analysis based on studies of four behavioural tasks. Brain Res Rev 2003; 41:268-287.
174. Slikker W, Beck BD, Cory-slechta DA, Paule M, Anger WK, Bellinger D. Cognitive tests: interpretation for neurotoxicity? (Workshop summary) Toxicol Sci 2000; 58:222-234.
175. Paule MG, Fogle CM, Allen RR, Pearson EC, Hammond TG, Popke EJ. Chronic exposure to NMDA receptor and sodium channel blockers during development in monkeys and rats: longterm effects on cognitive function. Ann NY Acad Sci 2002; 993:116-122.
176. Haefely W. Biological basis of drug-induced tolerance, rebound and dependence. Contribution of recent research on benzodiazepines. Pharmacopsychiatry 1986; 19:353-361.
177. Mansbach RS, Feltner DE, Gold LH, Schnoll SH. Incorporating the assessment of abuse liability into the drug discovery and development process. Drug Alcohol Depend 2003; 70:S73-S85.
178. Balster RL, Bigelow GE. Guidelines and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend 2003; 70:S13-S40.
179. Ator NA, Griffiths RR. Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend 2003; 70:S55-S72.
180. Tzschentke TM. Measuring reward with the conditioned place preference paradigm: a comprehensive review of drug effects, recent progress and new issues. Prog Neurobiol 1998; 56:613-672.
181. Bardo MT, Bevins RA. Conditioned place preference: what does it add to our preclinical understanding of drug reward? Psychopharmacol 2000; 153:31-43.
182. Colpaert FC. Drug discrimination in neurobiology. Pharmacol Biochem Behav 1999; 64:337-345.
183. Ator NA. Contributions of GABAA receptor subtype selectivity to abuse liability and dependence potential of pharmacological treatments for anxiety and sleep disorders. CNS Spectr 2005; 10:31-39.
184. Committee for Medicinal Products for Human Use Guideline on the non-clinical investigation of the dependence potential of medicinal products 2005. EMEA/CHMP/SWP/94227/2004.
185. Murphy DJ. Assessment of respiratory function in safety pharmacology. Fund Clin Pharmacol 2002; 16:183-196.
186. Ben-Noun L. Drug-induced respiratory disorders: incidence, prevention and management. Drug Saf 2000; 23:143-164.
187. Feldman JL, Mitchell GS, Nattie EE. Breathing: rhythmicity, plasticity, chemosensitivity. Ann Rev Neurosci 2003; 26:239-266.
188. American Thoracic Society. Lung function testing: selection of reference values and interpretive strategies. Am Rev Resp Dis 1991; 144:1202-1218.
189. Chong BT, Agrawal DK, Romero FA, Townley RG. Measurement of bronchoconstriction using whole-body plethysmograph: comparison of freely-moving versus restrained guineapigs. J Pharmacol Toxicol Methods 1998; 39:163-168.
190. DeLorme MP, Moss OR. Pulmonary function assessment by whole-body plethysmography in restrained versus unrestrained mice. J Pharmacol Toxicol Methods 2002; 47:1-10.
191. Mitzner W, Tankersley C, Lundblad LK, Adler A, Irvin CG, Bates JH. Interpreting Penh in mice. J Appl Physiol 2003; 94:828-832.
192. Bates J, Irvin C, Brusasco V, et al. The use and misuse of Penh in animal models of lung disease. Am J Respir Cell Mol Biol 2004; 32:373-374.
193. Murphy DJ, Joran ME, Grando JC. A non-invasive method for distinguishing central from peripheral nervous system effect of respiratory depressant drugs in conscious rats. Gen Pharmacol 1995; 26:569-575.
194. Ide T, Shirahata M, Chou CL, Fitzgerald RS. Effects of a continuous infusion of dopamine on the ventilatory and carotid body responses to hypoxia in cats. Clin Exp Pharmacol Physiol 1995; 22:658-664.
195. Pennock BE, Cox CP, Rogers RM, Cain WA, Wells JH. A non-invasive technique for measurement of changes in specific airway resistance. J Appl Physiol 1979; 46:39-106.
196. Murphy DJ, Renninger JP, Gossett KA. A novel method for chronic measurement of pleural pressure in conscious rats. J Pharmacol Toxicol Methods 1998; 39:137-141.
197. Murphy DJ, Renninger JP, Coatney RW. A novel method for chronic measurement of respiratory function in the conscious monkey. J Pharmacol Toxicol Methods 2001; 46:13-20.
198. Kanairo M, Shibata O, Saito M, Yoshimura M, Makita T, Sumikawa K. Effects of vasopressors on contractile and phosphatidylinositol responses of rat trachea. J Anesthesia 2002; 16:289-293.
199. Nyhlen K, Rippe B, Hultkvist-Bengtsson U. An isolated blood-perfused guinea-pig lung model for simultaneous registration of haemodynamic, microvascular and respiratory variables. Acta Physiol Scand 1997; 159:293-302.
200. Tsai MC. Effect of neomycin on post-tetanic twitch tension of the mouse diaphragm preparation. Br J Pharmacol 1987; 90:625-633.
201. Ramnarine SI, Liu YC, Rogers DF. Neuroregulation of mucus secretion by opioid receptors and K(ATP) and BK(Ca) channels in ferret trachea in vitro. Br J Pharmacol 1998; 123:1631-1638.
202. Dimova S, Maes F, Brewster ME, Jorissen M, Noppe M, Augustijns P. High-speed digital imaging method for ciliary beat frequency measurement. J Pharm Pharmacol 2005; 57:521-526.
203. Harrison AP, Erlwanger KH, Elbrønd, Anderson NK, Unmack MA. Gastrointestinal-tract models and techniques for use in safety pharmacology. J Pharmacol Toxicol Methods 2004; 49:187-199.
204. Mittelstadt SW, Hemenway CL, Spruell RD. Effects of fasting on evaluation of gastrointestinal transit with charcoal meal. J Pharmacol Toxicol Methods 2005; 52:154-158.
205. Yeung CK, McCurrie JR, Wood D. A simple method to investigate the inhibitory effects ofdrugs on gastric emptying in the mouse in vivo. J Pharmacol Toxicol Methods 2001; 45:235-240.
206. Papasouliotis K, Gruffydd-Jones TJ, Sparkes AH, Cripps PJ. A comparison of orocaecal transit times assessed by the breath hydrogen test and the sulphasalazine/sulphapyridine method in healthy beagle dogs. Res Vet Sci 1995; 58:263-267.
207. Nguyen A, Camilleri M, Kost LJ, et al. SDZ HTF 919 stimulates canine colonic motility and transit in vivo. J Pharmacol Exp Ther 1997; 280:1270-1276.
208. Iwanaga Y, Wen J, Thollander MS, et al. Scintigraphic measurement of regional gastrointestinal transit in the dog. Am J Physiol 1998; 275:G904-G910.
209. Gacsalyi U, Zabielski R, Pierzynowski SG. Telemetry facilitates long-term recording of gastrointestinal myoelectrical activity in pigs. Exp Physiol 2000; 85:239-241.
210. Chiu PJ, Barnett A, Tetzloff G, Kaminski J. Gastric antisecretory properties of SCH 32651. Arch Int Pharmacodyn Ther 1984; 270:116-127.
211. Patten GS, Head RJ, Abeywardena MY, McMurchie EJ. An apparatus to assay opioid activity in the infused lumen of the intact isolated guinea-pig ileum. J Pharmacol Toxicol Methods 2001; 45:39-46.
212. Coupar IM, Lu L. A simple method for measuring the effects of drugs on intestinal longitudinal and circular muscle. J Pharmacol Toxicol Methods 1996; 36:147-154.
213. Percy WH. In vitro techniques for the study of gastrointestinal motility. In: Gaginella TS, ed. Handbook ofMethods in Gastrointestinal Pharmacology. New York: CRC Press, 1996:189-224.
214. Ichihara K, Okumura K, Kamei H, et al. Renal effects of the calcium channel blocker aranidipine and its active metabolite in anesthetized dogs and conscious spontaneously hypertensive rats. J Cardiovasc Pharmacol 1998; 31:277-285.
215. Ronnhedh C, Jaquenod M, Mather LE. Urineless estimation of glomerular filtration rate and renal plasma flow in the rat. J Pharmacol Toxicol Methods 1996; 36:123-129.
216. Valentin JP, Mazbar SA, Humphreys MH. Long-term captopril treatment restores natriuresis after carotid baroreceptor activation in the SHR. Am J Physiol 1997; 273:R70-R79.
217. Neylon M, Marshall JM, Johns EJ. The effects of chronic hypoxia on renal function in the rat. J Physiol 1997; 501:243-250.
218. Fischer PA, Bogoliuk CB, Ramirez AJ, Sanchez RA, Masnatta LD. A new procedure for evaluation of renal function without urine collection in rat. Kidney Int 2000; 58:1336-1341.
219. Cambridge D, Whiting MV, Allan G. Cardiac and renovascular effects in the anaesthetized dog of BW A575C: a novel angiotensin converting enzyme inhibitor with beta-adrenoceptor blocking properties. Br J Pharmacol 1988; 93:165-175.
220. Brooks DP, Edwards RM, Depalma PD, Fredrickson TA, Hieble JP, Gellai M. The water diuretic effect of the alpha-2 adrenoceptor agonist, AGN 190851, is species-dependent. J Pharmacol Exp Ther 1991; 259:1277-1282.
221. Lenz T, Sealey JE, Maack T, et al. Half-life, hemodynamic, renal, and hormonal effects of prorenin in cynomolgus monkeys. Am J Physiol 1991; 260:R804-R810.
222. Supanz S, Sadjak A, Fellier H, Eidenberger T. Effects of the novel thromboxane (TXA2) receptor antagonist linotroban on inulin and para-aminohippuric acid clearances in the conscious male and female rat. ArzneimForsch 1997; 47:1026-1030.
223. Laurent D, Poirier K, Wasvary J, Rudin M. Effect of essential hypertension on kidney function as measured in rat by dynamic MRI. Magn Reson Med 2002; 47:127-134.
224. Pedersen M, Shi Y, Anderson P, et al. Quantitation of differential renal blood flow and renal function using dynamic contrast-enhanced MRI in rats. Magn Reson Med 2004; 51:510-517.
225. Maril N, Margalit R, Mispelter J, Degani H. Functional sodium magnetic resonance imaging of the intact rat kidney. Kidney Int 2004; 65:927-935.
226. Fry CH. Experimental models to study the physiology, pathophysiology, and pharmacology of the lower urinary tract. J Pharmacol Toxicol Methods 2004; 49:201-210.
227. Vera PL, Nadelhaft I. Effects of the atypical neuroleptic clozapine on micturition parameters in anesthetized rats. Neurourol Urodynamics 2001; 20:623-639.
228. Myers RA, Plym MJ, Signor LJ, Lodge NJ. 1-(2-pyrimidinyl)-piperazine, a buspirone metabolite, modulates bladder function in the anesthetized rat. Neurourol Urodynamics 2004; 23:709-715.
229. le Feber J, van Asselt E, van Mastrigt R. Afferent bladder nerve activity in the rat: a mechanism for starting and stopping voiding contractions. Urol Res 2004; 32:395-405.
230. Ghoniem GM, Aertker MW, Sakr MA, Shaaban AM, Shoukry MS. A telemetric multichannel computer-based system for monitoring urodynamic parameters in awake rhesus monkeys. J Urol 1997; 157:704-709.
231. Zbinden G. Predictive value of animal studies in toxicology. Regul Toxicol Pharmacol 1991; 14:167-177.
232. Zbinden G. Neglect of function and obsession with structure in toxicity testing. Proceedings of 9th International Congress Pharmacology. Vol. 1. New York: Macmillan, 1984:43-49.
233. Matsuzawa T, Hashimoto M, Nara N, Yoshida M, Tamura S, Igarashi T. Current status of conducting function tests in repeated dose toxicity studies in Japan. J Toxicol Sci 1997; 22:375-382.
234. Luft J, Bode G. Integration of safety pharmacology endpoints into toxicology studies. Fund Clin Pharmacol 2002; 16:91-103.
235. Vicini S, Ortinski P. Genetic manipulations of GABAA receptor in mice make inhibition exciting. Pharmacol Ther 2004; 103:109-120.
236. Roselt P, Meikle S, Kassiou M. The role of positron emission tomography in the discovery and development of new drugs; as studied in laboratory animals. Eur J Drug Metab Pharmacokinetics 2004; 29:1-6.
237. Lorenz JN. A practical guide to evaluating cardiovascular, renal, and pulmonary function in mice. Am J Physiol Regul Integr Comp Physiol 2002; 282:R1565-R1582.
238. Yang XP, Liu YH, Rhaleb NE, Kurihara N, Kim HE, Carretero OA. Echocardiographic assessment of cardiac function in conscious and anesthetized mice. Am J Physiol 1999; 277:H1967-H1974.
239. Collins KA, Korcarz CE, Lang RM. Use of echocardiography for the phenotypic assessment of genetically altered mice. Physiol Genomics 2003; 13:227-239.
240. Badea CT, Fubara B, Hedlund LW, Johnson GA. 4-D micro-CT of the mouse heart. Mol Imaging 2005; 4:110-116.
241. Kramer K, Kinter L, Brockway BP, Voss HP, Remie R, Van Zutphen BL. The use of radiotelemetry in small laboratory animals: recent advances. Contemp Top Lab Anim Sci 2001; 40:8-16.
242. Kramer K, Kinter LB. Evaluation and applications of radiotelemetry in small laboratory animals. Physiol Genomics 2003; 13:197-205.
243. Prinzen FW, Bassingthwaighte JB. Blood flow distributions by microsphere deposition methods. Cardiovasc Res 2000; 45:13-21.
244. AristizabalO, TurnbullDH. 44-MHzLiNbO3 transducers forUBM-guidedDopplerultrasound. IEEE Transactions on Ultrasonics Ferroelectrics & Frequency Control 2003; 50:623-630.
245. DeGeorge JD, Ahn C-H, Andrews PA, et al. Regulatory considerations for preclinical development of anticancer drugs. Cancer Chemother Pharmacol 1998; 41:173-185.
246. Tomaszewski JE. Multi-species toxicology approaches for oncology drugs: the U.S. perspective. Eur J Cancer 2004; 40:907-913.
247. Lallana EC, Abrey LE. Update on the therapeutic approaches to brain tumors. Expert Rev Anticancer Ther 2003; 3:655-670.
248. Wiedmann MW, Caca K. Molecularly targeted therapy for gastrointestinal cancer. Curr Cancer Drug Targets 2005; 5:171-193.
249. Isobe T, Herbst RS, Onn A. Current management of advanced non-small cell lung cancer: targeted therapy. Semin Oncol 2005; 32:315-328.
250. Foulkes R. Preclinical safety evaluation of monoclonal antibodies. Toxicology 2002; 174:21-26.
251. Yang H, Hang H, Czura CJ, Tracey KJ. The cytokine activity of HMGB1. J Leukocyte Biol 2005; 78:1-8.
252. Aptula AO, Cronin MTD. Prediction of herg KC blocking potency: application of structural knowledge. SAR and QSAR Environ Res 2004; 15:399-411.
253. Krejsa CM, Horvath D, Rogalski SL, et al. Predicting ADME properties and side effects: the BioPrint approach. Curr Opin Drug Discov Dev 2003; 6:470-480.
254. Engelberg A. Iconix Pharmaceuticals. Inc.-removing barriers to efficient drug discovery through chemogenomics. Pharmacogenomics 2004; 5:741-744.
255. Norinder U, Haeberlein M. Computational approaches to prediction of the blood-brain distribution. Adv Drug Deliv Rev 2002; 54:291-313.
256. Noble D, Levin J, Scott W. Biological simulations in drug discovery. Drug Discov Today 1999; 4:10-16.
257. Bottino D, Penland RC, Stamps A, et al. Preclinical cardiac safety assessment of pharmaceutical compounds using an integrated systems-based computer model of the heart. Prog Biophysics Mol Biol 2006; 90:414-443.
258. Wakefield ID, Pollard CE, Redfern WS, Hammond TG, Valentin J-P. The application of in vitro methods to safety pharmacology. Fund Clin Pharmacol 2002; 16:209-218.
259. Rubinstein AL. Zebrafish: from disease modelling to drug discovery. Curr Opin Drug Discov Dev 2003; 6:218-223.
260. Parng C. In vivo zebrafish assays for toxicity testing. Curr Opin Drug Discov Dev 2005; 8:100-106.
261. Zon LI, Peterson RT. In vivo drug discovery in the zebrafish. Nature Rev Drug Discov 2005; 4:35-44.
262. Neuhauss SCF. Behavioural genetic approaches to visual system development and function in zebrafish. J Neurobiol 2003; 54:148-160.
263. Bang PI, Yelick PC, Malicki JJ, Sewell WF. High-throughput behavioural screening method for detecting auditory response defects in zebrafish. J Neurosci Methods 2002; 118:177-187.
264. www.biologicsconsulting.com/Preclinical_PharmTox.htm.
265. Porsolt RD, Picard S, Lacroix P. International Safety Pharmacology Guidelines (ICH S7A and S7B): Where Do We Go from Here? Drug Dev Res 2005; 64:83-89.
266. Kinter LB, Siegl PK, Bass AS. New preclinical guidelines on drug effects on ventricular repolarization: safety pharmacology comes of age. J Pharmacol Toxicol Methods 2004; 49:153-158.
267. Morganroth J. Design and Conduct of the Thorough Phase I ECG Trial for New Bioactive Drugs. In: Morganroth J, Gussak I, eds. Cardiac Safety of Noncardiac Drugs: Practical Guidelines for Clinical research and Drug Development. New Jersey: Humana Press, 2005:205-222.
268. Shah RR. Drugs, QT interval prolongation and ICH E14: the need to get it right. Drug Safety 2005; 28:115-125.